Antonio M. Gotto

EFFECTS OF LONGER-TERM TREATMENT WITH ANACETRAPIB ON SAFETY PARAMETERS, LIPIDS, AND PLASMA DRUG CONCENTRATIONS IN THE DEFINE TRIAL

Anacetrapib is a cholesteryl ester transfer protein inhibitor that has previously been shown to be well tolerated, reduce low-density lipoprotein cholesterol (LDL-C) and raise high-density lipoprotein cholesterol (HDL-C) in patients with or at high risk for coronary heart disease in the DEFINE base